S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
SYRE · Spyre Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Spyre Therapeutics Inc (SYRE)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$92.90
+1.51
(+1.65%)
● At close: October 21 at 4:00:00 PM EDT
$92.95
+0.00
(+0.00%)
Overnight:
8:26:25 PM EDT
DAY'S RANGE
$92.90
$92.34
$94.83
52-WEEK RANGE
$92.90
$21.14
$110.17
What's happening
- SYRE is up 1.65% today, trading at $92.90. — Live quote
- Volume today (77,902) is well below its 3-month average of 1,368,880. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.36 actual vs. $-0.77 estimated (+53.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 11
Buy 9
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (22 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SYRE
+179.00%
vs S&P 500
+166.22%
1-YEAR RETURN
SYRE
+289.10%
vs S&P 500
+274.54%
6-MONTH RETURN
SYRE
+31.13%
3-MONTH RETURN
SYRE
-11.00%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.36
Est. $-0.77
BEAT +53.5%
2026-04-26 (Q1 2026)
$-0.74
Est. $-0.68
MISS -8.9%
2026-01-26 (Q4 2025)
$-0.70
Est. $-0.79
BEAT +11.4%
2025-10-26 (Q3 2025)
$-0.15
Est. $-0.76
BEAT +80.3%
Valuation Measures & Ratios
Enterprise Value4$8.42B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)6977.38
Price / Book77.00
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin-22158.54%
Operating Margin-17559.35%
Return on Equity (ROE8)-24.32%
Return on Assets (ROA9)-22.23%
Avg Volume (3M)1,368,880
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | $4.71B | — | — | — |
| P/E | — | -29.10 | — | — | — |
| Price/Book | — | 7.01 | — | — | — |
| ROE | — | -24.10% | — | — | — |
| ROA | — | -21.16% | — | — | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short12,844,608
Change from Prior Settlement+5.90%
% of Float—
Days to Cover (Short Ratio)8.89
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +289.1%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -22158.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-07; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SYRE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| Operating income | -$41.6M | -$45.6M | -$56.9M | -$41.9M | -$53.6M | -$55.4M | -$44.1M | -$47.8M |
| Net income | -$36.2M | -$69.0M | -$11.2M | -$36.7M | -$44.8M | -$69.0M | -$38.8M | -$43.9M |
| EPS (diluted) | — | $-0.74 | — | — | — | $-1.36 | $-0.86 | $-1.20 |
| EPS (basic) | — | — | — | — | — | $-1.36 | $-0.86 | $-1.20 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.17B | $764.0M | $777.8M | $504.6M | $538.8M | $569.8M | $608.5M | $421.1M |
| Total liabilities | $71.9M | $93.1M | $62.5M | $49.5M | $83.1M | $87.2M | $90.7M | $93.7M |
| Stockholders' equity | $1.10B | $670.8M | $715.2M | $455.1M | $455.8M | $482.6M | $517.8M | $327.4M |
| Total current assets | $1.17B | $764.0M | $777.8M | $504.6M | $538.8M | $569.8M | $608.5M | $421.1M |
| Total current liabilities | $63.3M | $85.2M | $58.7M | $46.3M | $83.1M | $70.7M | $54.1M | $57.5M |
| Cash & equivalents | $162.0M | $97.2M | $85.7M | $64.9M | $81.7M | $48.5M | $89.4M | $71.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | $0 | $0 | $0 | $10.0K | $10.0K | $10.0K |
| Accounts payable | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $1.3M | $1.3M | $0 | — | — | — | — | — |
| Common stock & paid-in capital | $16.0K | $15.0K | $15.0K | $13.0K | $13.0K | $13.0K | $13.0K | $12.0K |
| Retained earnings | -$1.23B | -$1.20B | -$1.13B | -$1.07B | -$1.05B | -$1.02B | -$972.4M | -$916.1M |
| Accumulated other comprehensive income (loss) | -$2.4M | -$767.0K | $869.0K | $791.0K | $454.0K | $682.0K | $180.0K | $1.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$69.9M | -$57.4M | -$44.6M | -$37.1M | -$46.6M | -$41.0M | -$37.2M | -$29.4M |
| Investing cash flow | -$297.9M | $56.6M | -$247.4M | $25.0M | $79.0M | -$61.0K | -$170.5M | $42.7M |
| Financing cash flow | $432.6M | $12.3M | $312.8M | -$4.6M | $731.0K | $125.0K | $225.6M | $12.8M |
| Free cash flow | — | — | — | — | — | — | -$37.2M | — |
| Capital expenditures | — | — | — | — | — | — | $0 | — |
| Depreciation & amortization | — | — | $0 | — | — | — | $0 | $0 |
| Share-based compensation | $13.5M | $12.8M | $9.8M | $9.6M | $9.4M | $8.9M | $31.0M | $13.1M |
| Change in accounts receivable | — | — | $0 | — | — | — | $0 | $0 |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $447.3M | $81.2M | $341.7M | $74.2M | $34.9M | $71.4M | $233.1M | $35.1M |
| Other financing activities | — | — | $0 | — | — | — | $1.0K | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886.0K | $2.3M | $18.7M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| EPS (diluted) | — | — | $-49.12 | $-24.86 | $-25.02 |
| EPS (basic) | — | — | $-49.12 | $-24.86 | $-25.02 |
| Operating margin | — | — | -$27.3K | -$3.6K | -$350 |
| Net margin | — | — | -$38.2K | -$3.6K | -$351 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Stockholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
| Total current assets | $777.8M | $608.5M | $341.5M | $62.3M | $98.9M |
| Total current liabilities | $58.7M | $54.1M | $32.0M | $14.7M | $20.1M |
| Cash & equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | — | — | $0 | $375.0K | $815.0K |
| Property, plant & equipment | — | — | $0 | $3.2M | $4.5M |
| Other non-current assets | $0 | $10.0K | $9.0K | $683.0K | $842.0K |
| Accounts payable | — | — | — | $677.0K | $3.3M |
| Deferred revenue (current) | — | — | $0 | $517.0K | $3.6M |
| Other non-current liabilities | — | — | — | $0 | $16.0K |
| Common stock & paid-in capital | $15.0K | $13.0K | $10.0K | $6.0K | $5.0K |
| Retained earnings | -$1.13B | -$972.4M | -$764.4M | -$425.6M | -$341.8M |
| Accumulated other comprehensive income (loss) | $869.0K | $180.0K | $302.0K | -$48.0K | -$20.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Investing cash flow | -$143.5M | -$353.3M | -$108.4M | $57.0M | -$22.6M |
| Financing cash flow | $309.0M | $410.9M | $361.1M | $42.7M | $1.4M |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Capital expenditures | — | $0 | $0 | $38.0K | $573.0K |
| Depreciation & amortization | $0 | $0 | $744.0K | $1.6M | $1.6M |
| Share-based compensation | $37.6M | $44.8M | $25.7M | $7.1M | $8.0M |
| Change in accounts receivable | $0 | $0 | -$375.0K | -$440.0K | $815.0K |
| Change in accounts payable | — | — | — | -$2.6M | $1.1M |
| Purchases of investments | $522.2M | $599.3M | $166.8M | $39.5M | $133.1M |
| Other financing activities | $0 | $1.0K | -$16.0K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SYRE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers92.1%
Shares Outstanding84,729,435
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 13,026,187 | $1.16B | 15.37% | +10.6% | 2026-08-13 |
| BlackRock, Inc. | 6,506,605 | $577.7M | 7.68% | +17.8% | 2026-08-07 |
| PERCEPTIVE ADVISORS LLC | 4,319,496 | $383.5M | 5.10% | +14.2% | 2026-08-14 |
| RTW INVESTMENTS, LP | 4,251,996 | $377.5M | 5.02% | +1.9% | 2026-08-14 |
| Paradigm Biocapital Advisors LP | 3,840,778 | $341.0M | 4.53% | +96.2% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,448,681 | $306.2M | 4.07% | +12.8% | 2026-06-30 |
| State Street Corp | 3,057,416 | $271.4M | 3.61% | +17.3% | 2026-08-07 |
| Venrock Adviser, LLC | 2,985,448 | $265.0M | 3.52% | -19.0% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,960,855 | $262.9K | 3.49% | +85.2% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,799,166 | $248.5M | 3.30% | +0.3% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,562,265 | $239.3M | 3.02% | +48.9% | 2026-08-12 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,330,098 | $206.9M | 2.75% | +298.2% | 2026-06-30 |
| Capital World Investors | 2,315,553 | $205.6M | 2.73% | +247.4% | 2026-08-07 |
| Jupiter Topco LLC | 2,206,936 | $195.9M | 2.60% | +0.0% | 2026-08-14 |
| TCG Crossover Management, LLC | 1,900,582 | $168.7M | 2.24% | +0.0% | 2026-08-12 |
| TANG CAPITAL MANAGEMENT LLC | 1,892,200 | $168.0M | 2.23% | +0.0% | 2026-08-14 |
| Bank Of America Corp /De/ | 1,777,854 | $157.8M | 2.10% | +44.8% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,722,300 | $152.9M | 2.03% | +0.0% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,581,505 | $140.4M | 1.87% | -13.3% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,478,059 | $131.2M | 1.74% | +447.6% | 2026-08-14 |
| Franklin Resources Inc | 1,472,943 | $130.8M | 1.74% | +66.8% | 2026-08-04 |
| Remedium Capital Partners, LLC | 1,464,169 | $130.0M | 1.73% | -23.2% | 2026-08-07 |
| Affinity Asset Advisors, LLC | 1,279,134 | $113.6M | 1.51% | +0.0% | 2026-08-13 |
| Jpmorgan Chase & Co | 1,093,026 | $98.9M | 1.29% | +11.6% | 2026-08-12 |
| Holocene Advisors, LP | 1,015,170 | $90.1M | 1.20% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-08 to 2026-10-01
Recent transactions
- Insiders have net sold 5,045,012 shares over the last 182 days, across 0 purchases and 64 sales.
- Most recent: King-Jones Heidy (See Remarks) — Option exercise of 28,933 shares on 2026-10-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)5,045,012 sh(64 txns)
Net Shares-5,045,012
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| King-Jones Heidy | See Remarks | Option exercise | 2026-10-01 | 28,933 |
| Turtle Cameron | Chief Executive Officer | Open market sale | 2026-10-01 | 600 |
| Burrows Scott L | Chief Financial Officer | Option exercise | 2026-10-01 | 7,500 |
| Albers Jeffrey W. | Director | Option exercise | 2026-08-07 | 5,000 |
| Sloan Sheldon | Chief Medical Officer | Option exercise | 2026-07-01 | 8,334 |
| Fairmount Funds Management LLC | Director | Derivative conversion | 2026-06-23 | 666,680 |
| HENDERSON MICHAEL THOMAS | Director | Open market sale | 2026-06-22 | 20,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | King-Jones Heidy | See Remarks | Option exercise | 28,933 | $14.50 |
| 2026-10-01 | King-Jones Heidy | See Remarks | Open market sale | 400 | $89.24 |
| 2026-10-01 | King-Jones Heidy | See Remarks | Open market sale | 16,605 | $90.35 |
| 2026-10-01 | King-Jones Heidy | See Remarks | Open market sale | 7,228 | $91.35 |
| 2026-10-01 | King-Jones Heidy | See Remarks | Open market sale | 2,100 | $92.70 |
| 2026-10-01 | King-Jones Heidy | See Remarks | Open market sale | 2,600 | $93.46 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 600 | $89.14 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 2,683 | $90.10 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 2,638 | $91.49 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 3,989 | $92.31 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 4,990 | $93.37 |
| 2026-10-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 100 | $93.91 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Option exercise | 7,500 | $14.50 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 600 | $89.07 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 1,500 | $90.27 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 2,100 | $91.92 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 3,071 | $92.95 |
| 2026-10-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 229 | $93.57 |
| 2026-09-30 | Burrows Scott L | Chief Financial Officer | Option exercise | 17,500 | $14.50 |
| 2026-09-30 | Burrows Scott L | Chief Financial Officer | Open market sale | 17,500 | $89.89 |
| 2026-09-02 | King-Jones Heidy | See Remarks | Option exercise | 400 | $14.50 |
| 2026-09-02 | King-Jones Heidy | See Remarks | Open market sale | 400 | $90.00 |
| 2026-09-02 | Burrows Scott L | Chief Financial Officer | Open market sale | 18,232 | $89.35 |
| 2026-09-01 | King-Jones Heidy | See Remarks | Option exercise | 27,999 | $14.50 |
| 2026-09-01 | King-Jones Heidy | See Remarks | Open market sale | 4,845 | $86.40 |
| 2026-09-01 | King-Jones Heidy | See Remarks | Open market sale | 16,548 | $87.20 |
| 2026-09-01 | King-Jones Heidy | See Remarks | Open market sale | 6,206 | $88.17 |
| 2026-09-01 | King-Jones Heidy | See Remarks | Open market sale | 400 | $89.38 |
| 2026-09-01 | Burrows Scott L | Chief Financial Officer | Option exercise | 7,500 | $14.50 |
| 2026-09-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 900 | $86.25 |
| 2026-09-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 4,384 | $87.11 |
| 2026-09-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 2,016 | $88.03 |
| 2026-09-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 200 | $89.04 |
| 2026-09-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 2,500 | $86.36 |
| 2026-09-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 8,400 | $87.15 |
| 2026-09-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 3,700 | $88.06 |
| 2026-09-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 400 | $89.07 |
| 2026-08-07 | Albers Jeffrey W. | Director | Option exercise | 5,000 | $10.39 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open market sale | 5,000 | $104.47 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open market sale | 8,000 | $104.38 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open market sale | 10,000 | $104.68 |
| 2026-08-03 | Burrows Scott L | Chief Financial Officer | Option exercise | 7,500 | $14.50 |
| 2026-08-03 | Burrows Scott L | Chief Financial Officer | Open market sale | 5,100 | $95.21 |
| 2026-08-03 | Burrows Scott L | Chief Financial Officer | Open market sale | 2,300 | $96.30 |
| 2026-08-03 | Burrows Scott L | Chief Financial Officer | Open market sale | 100 | $97.10 |
| 2026-08-03 | Turtle Cameron | Chief Executive Officer | Open market sale | 800 | $93.97 |
| 2026-08-03 | Turtle Cameron | Chief Executive Officer | Open market sale | 7,157 | $95.10 |
| 2026-08-03 | Turtle Cameron | Chief Executive Officer | Open market sale | 5,635 | $95.93 |
| 2026-08-03 | Turtle Cameron | Chief Executive Officer | Open market sale | 1,392 | $96.82 |
| 2026-08-03 | Turtle Cameron | Chief Executive Officer | Open market sale | 16 | $97.46 |
| 2026-07-01 | Burrows Scott L | Chief Financial Officer | Option exercise | 7,500 | $14.50 |
| 2026-07-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 5,775 | $87.55 |
| 2026-07-01 | Burrows Scott L | Chief Financial Officer | Open market sale | 1,725 | $88.37 |
| 2026-07-01 | Sloan Sheldon | Chief Medical Officer | Option exercise | 8,334 | $27.46 |
| 2026-07-01 | Sloan Sheldon | Chief Medical Officer | Open market sale | 6,500 | $87.52 |
| 2026-07-01 | Sloan Sheldon | Chief Medical Officer | Open market sale | 1,834 | $88.34 |
| 2026-07-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 10,176 | $87.44 |
| 2026-07-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 4,234 | $88.12 |
| 2026-07-01 | Turtle Cameron | Chief Executive Officer | Open market sale | 590 | $88.91 |
| 2026-06-25 | Burrows Scott L | Chief Financial Officer | Option exercise | 15,000 | $14.50 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:16 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-07 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-07 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
Recent news
Headlines about SYRE (Spyre Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
SYRE Stock Whipsaws As Bullish Targets Clash With Dilution Hit
StocksToTrade · 2026-10-20 -
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
Yahoo · 2026-10-20 -
BTIG reiterates Buy rating on Spyre Therapeutics, $121 price target
TradingView · 2026-10-19 -
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
Benzinga · 2026-10-19 -
How Investors May Respond To Spyre Therapeutics (SYRE) IBD Antibody Data
Simply Wall Street · 2026-10-19 -
Spyre Therapeutics (SYRE) Stock Forecast and Price Target 2026 $SYRE
MarketBeat · 2026-10-19 -
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Yahoo · 2026-10-18 -
SYRE Jan 2027 105.000 put (SYRE270115P00105000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18
No headlines in this category right now — try “All”.